CRNX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Crinetics Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was $45.13 Mil.
Crinetics Pharmaceuticals's quarterly Long-Term Capital Lease Obligation declined from Mar. 2024 ($46.71 Mil) to Jun. 2024 ($45.87 Mil) and declined from Jun. 2024 ($45.87 Mil) to Sep. 2024 ($45.13 Mil).
Crinetics Pharmaceuticals's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($3.07 Mil) to Dec. 2022 ($2.02 Mil) but then increased from Dec. 2022 ($2.02 Mil) to Dec. 2023 ($47.56 Mil).
The historical data trend for Crinetics Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crinetics Pharmaceuticals Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Long-Term Capital Lease Obligation | Get a 7-Day Free Trial | 4.85 | 4.01 | 3.07 | 2.02 | 47.56 |
Crinetics Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Long-Term Capital Lease Obligation | Get a 7-Day Free Trial | 48.18 | 47.56 | 46.71 | 45.87 | 45.13 |
Crinetics Pharmaceuticals (NAS:CRNX) Long-Term Capital Lease Obligation Explanation
Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.
Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:
1. Ownership of the asset is transferred to the lessee at the end of the lease term;Thank you for viewing the detailed overview of Crinetics Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Scott Struthers | director, officer: See Remarks | C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121 |
Jeff E. Knight | officer: Chief Operating Officer | CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121 |
Dana Pizzuti | officer: Chief Development Officer | C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121 |
Marc Wilson | officer: See Remarks | 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Stephen F. Betz | officer: Chief Scientific Officer | 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121 |
James Hassard | officer: Chief Commercial Officer | 177 E COLORADO BLVD, STE 700, PASADENA CA 91105 |
Stephanie Okey | director | C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109 |
Matthew K Fust | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Alan Seth Krasner | officer: Chief Medical Officer | C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121 |
Vivaldi Coelho Rogerio | director | 225 SECOND AVENUE, WALTHAM MA 02451 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Caren Deardorf | director | C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Ajay Madan | officer: Chief Development Officer | C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. 2, SAN DIEGO CA 92121 |
Camille L Bedrosian | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Vivo Capital Fund Viii, L.p. | 10 percent owner | 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301 |
From GuruFocus
By GuruFocus Research • 07-26-2024
By Marketwired • 11-11-2024
By GuruFocus Research • 09-12-2024
By Marketwired • 11-14-2024
By GuruFocus News • 10-09-2024
By Marketwired • 10-16-2024
By Marketwired • 08-29-2024
By Marketwired • 11-15-2024
By GuruFocus News • 10-17-2024
By Marketwired • 08-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.